Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 17/20 | 0.57 |
| ▸ | FPR3 | P25089 | 2/20 | 0.39 |
| ▸ | TSPO | P30536 | 2/20 | 0.39 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4602046 | 1.00 | CRHR1 (0.57) | CRHR1FPR3TSPOTMEM97 | |
| SCHEMBL7353524 | 0.89 | CRHR1 (0.57) | CRHR1FPR3TSPOTMEM97 | |
| SCHEMBL7356524 | 0.89 | CRHR1 (0.62) | CRHR1FPR3TSPOTMEM97 | |
| SCHEMBL7359092 | 0.87 | CRHR1 (0.53) | CRHR1FPR3TSPOTMEM97 | |
| SCHEMBL7355489 | 0.84 | CRHR1 (0.62) | CRHR1FPR3TSPOTMEM97 | |
| SCHEMBL7358693 | 0.83 | CRHR1 (0.60) | CRHR1FPR3TSPOTMEM97 | |
| SCHEMBL7360292 | 0.72 | CRHR1 (0.70) | CRHR1 | |
| Hydrochloric Acid SCHEMBL8127656 | 0.72 | CRHR1 (0.69) | CRHR1 | |
| SCHEMBL1636385 | 0.71 | CRHR1 (0.43) | CRHR1FPR3TSPOTMEM97 | |
| SCHEMBL8498539 | 0.70 | CRHR1 (0.54) | CRHR1FPR3TSPOTMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6387894-B1 | MIXTURE OF CORTICOTROPIN RELEASING FACTOR ANTAGINIST AND RENIN-ANGIOTENSIN SYSTEM INHIBITOR; THERAPY FOR CONGESTIVE HEART FAILURE, HYPOTENSIVE AGENTS | PFIZER INC. | 2002-05-14 | — | — | US | claimed |
| US-6384039-B1 | ADMINISTERING CORTICOTROPIN RELEASING FACTOR ANTAGONIST | PFIZER INC. | 2002-05-07 | — | — | US | claimed |
| US-20010000340-A1 | New uses for corticotropin releasing factor antagonists | CHEN YUHPYNG L (US) | 2001-04-19 | — | — | US | claimed |
| EP-1059100-A2 | Combinations of CRF antagonists and renin-angiotensin system inhibitors | Pfizer Products Inc. (US) | 2000-12-13 | — | — | EP | claimed |
| EP-1040831-A2 | Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death | Pfizer Products Inc. (US) | 2000-10-04 | — | — | EP | claimed |
| US-6051578-A | Pyrazolopyrimidines for treatment of CNS disorders | PFIZER INC. (US) | 2000-04-18 | — | — | US | claimed |
| EP-0773023-A1 | New uses for corticotropin releasing factor (CRF) antagonists | PFIZER INC. (US) | 1997-05-14 | — | — | EP | claimed |
| EP-0729758-A2 | Pyrazolopyrimidines and pyrrolopyrimidines for treatment of neuronal and other disorders | PFIZER INC. (US) | 1996-09-04 | — | — | EP | claimed |
| US-6403599-B1 | STROKE, HYPERTENSION, TACHYCARDIA, AND CONGESTIVE HEART FAILURE, OSTEOPOROSIS, PREMATURE BIRTH, PSYCHOSOCIAL DWARFISM, STRESS-INDUCED FEVER, ULCER, DIARRHEA, POST-OPERATIVE ILEUS, AND COLONIC HYPERSENSITIVITY, CARDIOVASCULAR DISORDERS | PFIZER INC | 2002-06-11 | — | — | US | disclosed |
| US-6387894-B1 | MIXTURE OF CORTICOTROPIN RELEASING FACTOR ANTAGINIST AND RENIN-ANGIOTENSIN SYSTEM INHIBITOR; THERAPY FOR CONGESTIVE HEART FAILURE, HYPOTENSIVE AGENTS | PFIZER INC. | 2002-05-14 | — | — | US | disclosed |
| US-20010000340-A1 | New uses for corticotropin releasing factor antagonists | CHEN YUHPYNG L (US) | 2001-04-19 | — | — | US | disclosed |
| EP-1059100-A2 | Combinations of CRF antagonists and renin-angiotensin system inhibitors | Pfizer Products Inc. (US) | 2000-12-13 | — | — | EP | disclosed |
| US-6051578-A | Pyrazolopyrimidines for treatment of CNS disorders | PFIZER INC. (US) | 2000-04-18 | — | — | US | disclosed |
| EP-0674641-B1 | PYRROLOPYRIMIDINES AS CRF ANTAGONISTS | PFIZER (US) | 1999-03-03 | — | — | EP | disclosed |
| EP-0773023-A1 | New uses for corticotropin releasing factor (CRF) antagonists | PFIZER INC. (US) | 1997-05-14 | — | — | EP | disclosed |
| EP-0729758-A2 | Pyrazolopyrimidines and pyrrolopyrimidines for treatment of neuronal and other disorders | PFIZER INC. (US) | 1996-09-04 | — | — | EP | disclosed |
| EP-0674641-A1 | PYRROLOPYRIMIDINES AS CRF ANTAGONISTS | PFIZER INC. (US) | 1995-10-04 | — | — | EP | disclosed |
| WO-1994013676-A1 | PYRROLOPYRIMIDINES AS CRF ANTAGONISTS | PFIZER INC. (US) | 1994-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010000340-A1 | New uses for corticotropin releasing factor antagonists | CRH, CRHR1, CRHR2 | CRHR1 2/4885FPR3 44/4885TSPO 2527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.